CDS2 Antibody

What is CDS2 and what cellular functions does it perform?

CDS2 (CDP-diacylglycerol synthase 2) is an enzyme that catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), which serves as an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin, and phosphatidylinositol . In humans, the canonical protein has a length of 445 amino acid residues and a molecular mass of 51.4 kDa with subcellular localization primarily in the endoplasmic reticulum (ER) . Beyond its basic enzymatic role, CDS2 exhibits specificity for the nature of acyl chains at the sn-1 and sn-2 positions in its substrate, with a preference for 1-stearoyl-2-arachidonoyl-sn-phosphatidic acid . Additionally, it plays an important role in regulating the growth and maturation of lipid droplets, which are storage organelles central to lipid and energy homeostasis .

What types of CDS2 antibodies are available for research applications?

Based on comprehensive antibody databases, several types of CDS2 antibodies are available:

Table 1: Types of CDS2 Antibodies Available for Research

These diverse antibody types enable researchers to select the optimal reagent based on their specific experimental requirements .

What applications are CDS2 antibodies validated for in research settings?

CDS2 antibodies have been validated for multiple research applications, with varying degrees of optimization:

• Western Blot (WB): The most widely used application, allowing detection and quantification of CDS2 protein in cell and tissue lysates. Typically detects a band at approximately 51.4 kDa .

• Enzyme-Linked Immunosorbent Assay (ELISA): Used for quantitative detection of CDS2 in solution. Many commercially available antibodies are validated for this application .

• Immunohistochemistry (IHC): For visualizing CDS2 distribution in tissue sections, including paraffin-embedded samples (IHC-P). Shows characteristic ER localization patterns .

• Immunocytochemistry (ICC) and Immunofluorescence (IF): Enables subcellular localization studies of CDS2, particularly valuable for co-localization experiments with other ER markers or lipid droplet proteins .

The selection of application should be guided by the specific research question and the validation data available for each antibody.

What are the critical factors for optimizing Western blot protocols with CDS2 antibodies?

Successful Western blot experiments with CDS2 antibodies require attention to several key factors:

• Sample preparation:

  • Use detergent-containing lysis buffers (e.g., RIPA buffer with protease inhibitors) to ensure efficient extraction of this membrane-associated protein

  • Sonication may improve extraction of ER-localized CDS2

  • Fresh samples typically provide better results than frozen/thawed samples due to the nature of membrane proteins

• Gel electrophoresis parameters:

  • 10-12% polyacrylamide gels are suitable for resolving the 51.4 kDa CDS2 protein

  • Loading 20-50 μg of total protein is typically sufficient for detection in cells/tissues with normal expression

• Transfer conditions:

  • Semi-dry or wet transfer systems both work effectively

  • Transfer efficiency should be verified with reversible protein stains before immunoblotting

• Blocking and antibody incubation:

  • 5% non-fat dry milk or BSA in TBST typically provides effective blocking

  • Primary antibody dilutions of 1:500-1:2000 are commonly effective (optimize for each specific antibody)

  • Overnight incubation at 4°C often yields better signal-to-noise ratio than shorter incubations

• Detection considerations:

  • Enhanced chemiluminescence detection is widely used and effective

  • Expected band at approximately 51.4 kDa; any additional bands should be carefully validated

These optimizations should be performed systematically, changing one variable at a time to identify optimal conditions.

How should researchers validate CDS2 antibody specificity before experimental use?

Thorough validation of CDS2 antibodies is essential before experimental use. A systematic validation approach includes:

• Western blot validation:

  • Confirm single band at expected molecular weight (~51.4 kDa)

  • Test in multiple cell lines or tissues with varying CDS2 expression levels

  • Include positive controls (tissues known to express CDS2) and negative controls (CRISPR knockout or siRNA knockdown samples)

• Immunohistochemistry/immunofluorescence validation:

  • Compare staining pattern with known CDS2 subcellular localization (ER)

  • Perform co-localization studies with established ER markers

  • Include appropriate controls: no primary antibody, isotype control, and blocking peptide competition

• Cross-validation strategies:

  • Compare results using different CDS2 antibodies targeting distinct epitopes

  • Correlate protein detection with mRNA expression data

  • Consider orthogonal approaches such as mass spectrometry confirmation of immunoprecipitated samples

• Advanced validation approaches:

  • Genetic strategy: Testing antibody in CDS2 knockout/knockdown models

  • Orthogonal strategy: Comparing antibody results with alternative detection methods

  • Independent antibody strategy: Using antibodies targeting different CDS2 epitopes

This multi-parameter validation approach minimizes the risk of misinterpreting results due to antibody cross-reactivity or non-specific binding.

What tissue preparation techniques optimize CDS2 detection in immunohistochemistry?

Successful CDS2 detection in immunohistochemistry requires careful attention to tissue preparation:

• Fixation considerations:

  • 10% neutral-buffered formalin is typically suitable for preserving CDS2 epitopes

  • Fixation duration should be optimized (typically 24-48 hours) to balance tissue preservation and antigen masking

  • For fresh-frozen sections, acetone or 4% paraformaldehyde fixation is recommended

• Antigen retrieval methods:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) is commonly effective

  • For some antibodies, EDTA buffer (pH 9.0) may provide superior results

  • Optimization of retrieval duration (typically 10-20 minutes) is crucial

• Section thickness:

  • 4-6 μm sections typically provide optimal results for CDS2 detection

  • Thinner sections may reduce antibody penetration issues but compromise signal intensity

• Blocking parameters:

  • Include steps to block endogenous peroxidase activity (for chromogenic detection)

  • Use species-appropriate normal serum (5-10%) or BSA (1-5%) for blocking non-specific binding sites

  • Consider additional blocking steps for endogenous biotin if using biotin-based detection systems

• Detection system selection:

  • Polymer-based detection systems often provide superior sensitivity with lower background

  • Tyramide signal amplification can enhance detection of low-abundance CDS2 expression

  • Fluorescent multiplexing allows co-localization studies with ER markers

Each of these parameters should be systematically optimized for the specific CDS2 antibody being used.

How can CDS2 antibodies be leveraged to study lipid droplet biogenesis and metabolism?

CDS2 plays an important role in regulating lipid droplet growth and maturation , making CDS2 antibodies valuable tools for investigating these processes:

• Temporal analysis of CDS2 recruitment:

  • Time-course immunofluorescence studies can track CDS2 localization during lipid droplet formation

  • Pulse-chase experiments combined with CDS2 immunostaining reveal dynamic recruitment patterns

  • Triple-labeling with lipid droplet markers (e.g., PLIN family proteins) and ER markers demonstrates spatial relationships

• Proximity analysis approaches:

  • Proximity ligation assays using CDS2 antibodies can identify interactions with other lipid droplet-associated proteins

  • FRET-based approaches using fluorescent CDS2 antibodies can measure nanoscale proximities to other proteins

  • Immunoelectron microscopy provides ultrastructural localization of CDS2 at lipid droplet-ER contact sites

• Functional studies:

  • Correlative analysis of CDS2 levels (via quantitative immunoblotting) with lipid droplet parameters (size, number)

  • CDS2 knockdown studies combined with rescue experiments using wild-type or mutant CDS2 (verified by antibody detection)

  • Pharmacological manipulation of CDP-DAG synthesis pathway combined with CDS2 immunolocalization

• Disease model investigations:

  • Compare CDS2 expression/localization in models of metabolic disorders using immunohistochemistry

  • Quantitative analysis of CDS2 in liver tissues from normal versus steatotic samples

  • Co-localization studies in adipose tissue under normal and pathological conditions

These approaches provide mechanistic insights into how CDS2 contributes to lipid droplet dynamics under normal and pathological conditions.

What techniques can optimize detection of CDS2 in protein complexes and interaction studies?

Studying CDS2 in protein complexes requires specialized approaches that preserve interactions while enabling specific detection:

• Co-immunoprecipitation optimization:

  • Gentle lysis conditions using digitonin or CHAPS instead of stronger detergents

  • Pre-clearing lysates with protein A/G beads to reduce non-specific binding

  • Cross-validation using reciprocal IPs with antibodies against suspected interaction partners

  • Confirmation of successful CDS2 precipitation using Western blot with a different CDS2 antibody

• Proximity-based interaction methods:

  • BioID or APEX2 proximity labeling combined with CDS2 antibody validation

  • In situ proximity ligation assay (PLA) using CDS2 antibodies paired with antibodies against candidate interactors

  • FRET/FLIM applications using directly labeled CDS2 antibodies or fragments

• Native complex preservation:

  • Blue native PAGE followed by CDS2 immunoblotting

  • Size exclusion chromatography of membrane extracts with subsequent immunodetection

  • Sucrose gradient ultracentrifugation combined with CDS2 immunoblotting of fractions

• Crosslinking strategies:

  • Membrane-permeable crosslinkers before cell lysis to stabilize transient interactions

  • Two-step immunoprecipitation protocols to maintain complex integrity

  • Mass spectrometry analysis of crosslinked complexes with CDS2 antibody confirmation

• Visualization of complexes:

  • Super-resolution microscopy using CDS2 antibodies with potential interactors

  • Live-cell imaging with subsequent fixation and CDS2 immunostaining at various timepoints

  • Correlative light and electron microscopy with CDS2 immunogold labeling

These approaches help overcome the challenges associated with studying membrane-associated protein complexes containing CDS2.

How do different clonality types of CDS2 antibodies affect experimental outcomes in advanced applications?

The choice between monoclonal and polyclonal CDS2 antibodies significantly impacts experimental outcomes, particularly in advanced applications:

Table 2: Comparative Performance of Monoclonal vs. Polyclonal CDS2 Antibodies

When selecting an antibody for advanced applications, researchers should consider not only detection sensitivity but also reproducibility requirements, risk of background interference, and whether multiple epitope recognition is advantageous for the specific experimental context .

What approaches can combine CDS2 antibodies with metabolic labeling to study phospholipid synthesis dynamics?

Integrating CDS2 antibody detection with metabolic labeling creates powerful approaches for studying phospholipid synthesis kinetics:

• Radiolabeled precursor incorporation:

  • Pulse-chase experiments with [³²P]orthophosphate or [³H]glycerol

  • Subcellular fractionation followed by immunoprecipitation with CDS2 antibodies

  • Analysis of labeled phospholipids associated with CDS2-containing fractions

  • Correlation between CDS2 protein levels (by immunoblotting) and CDP-DAG synthesis rates

• Click chemistry approaches:

  • Alkyne/azide-modified fatty acid incorporation into phospholipids

  • Cell fixation and permeabilization followed by click reaction and CDS2 immunostaining

  • Visualization of newly synthesized phospholipids in relation to CDS2 localization

  • Super-resolution imaging to visualize spatial relationships

• Mass spectrometry integration:

  • Stable isotope labeling of lipid precursors

  • CDS2 immunoprecipitation of protein complexes

  • Lipidomic analysis of associated phospholipids

  • Correlation of CDS2 expression levels with lipid composition changes

• Combined genomic and immunological approaches:

  • CRISPR-mediated tagging of CDS2 with fluorescent proteins

  • Validation of tagged protein with CDS2 antibodies

  • Live imaging combined with lipid probes

  • Fixation and additional immunostaining for other pathway components

These integrated approaches link CDS2 protein dynamics directly to its enzymatic function in phospholipid synthesis, providing mechanistic insights beyond simple expression analysis.

What strategies can resolve weak or inconsistent CDS2 signal in Western blot applications?

When encountering weak or inconsistent CDS2 signals in Western blots, systematic troubleshooting approaches include:

• Sample preparation optimization:

  • Enhance extraction of ER-localized CDS2 using specialized membrane protein extraction buffers

  • Include phosphatase inhibitors (CDS2 may be regulated by phosphorylation)

  • Process samples quickly and maintain cold temperatures to minimize protein degradation

  • Consider sample concentration methods for low-abundance samples

• Gel and transfer parameter adjustments:

  • Optimize acrylamide percentage (10-12% typically best for 51.4 kDa CDS2)

  • Try both wet and semi-dry transfer methods to identify optimal conditions

  • Adjust methanol concentration in transfer buffer (lower for better transfer of hydrophobic proteins)

  • Extended transfer times or lower voltage may improve transfer efficiency

• Primary antibody optimization:

  • Test multiple dilutions to identify optimal concentration

  • Extend incubation time (overnight at 4°C often yields better results)

  • Compare different CDS2 antibodies targeting distinct epitopes

  • Ensure antibody storage conditions maintain activity (aliquot to prevent freeze-thaw cycles)

• Detection system enhancement:

  • Try more sensitive detection substrates for HRP-conjugated secondaries

  • Consider signal amplification systems (e.g., biotin-streptavidin)

  • Increase exposure time incrementally to capture weak signals

  • For fluorescent detection, adjust scanner settings and use appropriate filters

• Methodological controls:

  • Include positive control lysates from tissues known to express CDS2

  • Run recombinant CDS2 protein as reference standard

  • Verify primary antibody activity with dot blot before full Western blot procedure

Systematic implementation of these strategies typically resolves most detection challenges for CDS2 Western blotting.

How can background issues in CDS2 immunohistochemistry be minimized?

High background in CDS2 immunohistochemistry can obscure specific signals. Resolution strategies include:

• Blocking optimization:

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Extend blocking time (60 minutes minimum, potentially overnight)

  • Include detergents (0.1-0.3% Triton X-100 or 0.05% Tween-20) to reduce non-specific binding

  • For fatty tissues, add additional lipid blockers like delipidated serum

• Antibody dilution and incubation conditions:

  • Increase primary antibody dilution incrementally (typically 1:100-1:500)

  • Use antibody diluent containing stabilizers and background reducers

  • Extend washing steps (number and duration) after antibody incubations

  • Incubate primary antibody at 4°C overnight rather than at room temperature

• Tissue-specific optimizations:

  • For high-lipid tissues, additional permeabilization steps may improve specificity

  • Optimize antigen retrieval duration based on tissue type

  • Pretreat sections with hydrogen peroxide (3%) to block endogenous peroxidases

  • For tissues with high biotin content, use biotin blocking kits before detection

• Detection system adjustments:

  • Switch from ABC systems to polymer-based detection for lower background

  • Dilute detection reagents further than manufacturer recommendations if background persists

  • Shorten substrate development time and monitor microscopically

  • Use fluorescent detection methods which often provide cleaner backgrounds

• Antibody validation approaches:

  • Test multiple CDS2 antibodies targeting different epitopes

  • Perform blocking peptide controls to identify non-specific binding

  • Include isotype controls at the same concentration as the primary antibody

Systematic implementation of these approaches typically resolves most background issues in CDS2 immunohistochemistry applications.

What controls are essential for validating CDS2 antibody specificity in various applications?

Proper controls are critical for validating CDS2 antibody specificity across applications:

Table 3: Essential Controls for CDS2 Antibody Validation

Using a combination of these controls increases confidence in the specificity of CDS2 antibody detection and helps distinguish true signals from artifacts or cross-reactivity .

What are the key considerations when using CDS2 antibodies for co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) with CDS2 antibodies presents specific challenges due to CDS2's membrane localization. Key considerations include:

• Lysis buffer optimization:

  • Use mild non-ionic detergents (0.5-1% NP-40, 0.5% digitonin) to solubilize membranes while preserving protein interactions

  • Include protease inhibitors, phosphatase inhibitors, and appropriate salt concentration (typically 150mM NaCl)

  • Avoid harsh detergents like SDS that disrupt protein-protein interactions

  • Consider supplementing with glycerol (5-10%) to stabilize protein complexes

• Antibody selection criteria:

  • Choose antibodies validated for immunoprecipitation applications

  • Consider using multiple CDS2 antibodies targeting different epitopes

  • For monoclonal antibodies, verify the epitope is accessible in native conditions

  • Determine optimal antibody-to-lysate ratio through titration experiments

• Bead selection and handling:

  • Pre-clear lysates with beads alone to reduce non-specific binding

  • Compare protein A, protein G, or combination beads for optimal antibody capture

  • Consider direct antibody conjugation to beads for cleaner results

  • Use gentle mixing (rotation rather than vortexing) to maintain complex integrity

• Elution strategies:

  • Gentle elution with antibody-specific peptides may preserve co-immunoprecipitated complexes

  • Compare acidic vs. reducing agent elution to determine optimal conditions

  • Sequential elution can help distinguish strongly vs. weakly associated proteins

• Critical controls:

  • "No antibody" bead control to identify non-specific bead binding

  • Isotype-matched irrelevant antibody control

  • Input sample (pre-IP lysate) to verify initial presence of proteins

  • Positive control IP with known CDS2-interacting protein antibody

• Downstream detection considerations:

  • Immunoblot with alternative CDS2 antibody (different from IP antibody)

  • Blot with antibodies against predicted interaction partners

  • Consider mass spectrometry analysis for unbiased interaction discovery

These considerations help overcome the challenges of Co-IP with membrane-associated proteins like CDS2, improving the likelihood of detecting genuine interaction partners.

How might new antibody engineering approaches enhance CDS2 antibody specificity and performance?

Recent advances in antibody engineering offer opportunities to develop improved CDS2 antibodies:

• Computational design optimization:

  • Methods like OptCDR can optimize complementarity-determining regions (CDRs) for enhanced specificity and affinity toward CDS2

  • Structure-based computational approaches can predict mutations that minimize cross-reactivity

  • Machine learning algorithms can analyze successful antibody-antigen interactions to guide rational design

• Recombinant antibody development:

  • Single-chain variable fragments (scFvs) targeting CDS2 may access epitopes restricted to full IgGs

  • Phage display selections with designed synthetic libraries can yield high-affinity CDS2 binders

  • Yeast surface display enables fine affinity discrimination and directed evolution

• Epitope-focused engineering:

  • Design of antibodies targeting conserved, functionally critical regions of CDS2

  • Development of conformation-specific antibodies that distinguish active vs. inactive CDS2

  • Creation of phospho-specific antibodies if CDS2 regulation involves phosphorylation sites

• Stability engineering:

  • Combining knowledge-based, statistical, and structure-based methods to enhance CDS2 antibody stability

  • This is particularly valuable for applications requiring robust performance in diverse conditions

  • Thermostable variants facilitate applications in harsh fixation conditions

• Novel detection formats:

  • Nanobodies (single-domain antibodies) may provide better access to sterically hindered epitopes

  • Bi-specific antibodies that simultaneously target CDS2 and a subcellular marker for improved localization studies

  • Split-antibody complementation systems for studying protein-protein interactions involving CDS2

These engineering approaches could address current limitations in CDS2 antibody performance, specificity, and application range.

What role might artificial intelligence play in future CDS2 antibody development?

Artificial intelligence is transforming antibody development with applications to CDS2 antibodies:

• Sequence-based optimization:

  • AI algorithms can analyze antibody-antigen interaction patterns from existing datasets

  • Machine learning models trained on successful antibodies predict optimal sequences for CDS2 binding

  • Natural language processing techniques apply to antibody sequence analysis for identifying binding patterns

• Epitope prediction and optimization:

  • AI can identify optimal epitopes on CDS2 for antibody targeting

  • Models balance accessibility, conservation, and immunogenicity in epitope selection

  • Structural prediction algorithms help identify surface-exposed regions of CDS2

• Off-target prediction:

  • AI methods predict potential cross-reactivity with proteins similar to CDS2

  • Algorithms based on both sequence and predicted 2D structure can identify potential off-targets

  • This capability is available as soon as antibody sequences are known, without requiring antigen 3D structure data

• Development pipeline acceleration:

  • AI significantly reduces traditional antibody development timelines

  • In silico screening narrows candidate pools before experimental validation

  • Deep learning models predict antibody developability (solubility, stability, manufacturability)

• Structure prediction integration:

  • Protein structure prediction tools (like AlphaFold) inform antibody design

  • 3D structural information improves epitope selection and antibody engineering

  • Molecular dynamics simulations predict binding energetics and kinetics

These AI-powered approaches could transform CDS2 antibody development by enhancing specificity, reducing development times, and predicting performance characteristics before experimental testing .

How might CDS2 antibodies contribute to emerging research in membrane contact sites and lipid transport?

CDS2 antibodies offer valuable tools for investigating emerging research areas:

• Organelle contact site studies:

  • CDS2 localizes to the ER , which forms contact sites with multiple organelles

  • Immunofluorescence with CDS2 antibodies combined with markers for other organelles can reveal functional contact sites

  • Super-resolution microscopy with CDS2 antibodies helps visualize nanoscale organization of these contacts

  • Proximity ligation assays using CDS2 antibodies with other contact site proteins reveal molecular organization

• Lipid transport investigations:

  • CDS2 produces CDP-DAG, a key intermediate in phospholipid synthesis

  • CDS2 antibodies can track enzyme localization during lipid transport events

  • Co-localization with lipid transfer proteins at membrane contact sites

  • Correlative light and electron microscopy with CDS2 immunogold labeling reveals ultrastructural context

• Metabolic disease models:

  • CDS2 involvement in lipid droplet growth and maturation links it to metabolic disorders

  • Quantitative immunohistochemistry can assess CDS2 alterations in tissue samples

  • Multiplexed imaging with other lipid metabolism markers creates comprehensive metabolic profiles

  • Single-cell analysis with CDS2 antibodies reveals heterogeneity in metabolic responses

• Therapeutic target assessment:

  • CDS2 pathway modulation may have therapeutic potential in lipid disorders

  • Antibodies provide tools to validate target engagement in drug development

  • Proximity-based assays can identify compounds that disrupt or enhance protein interactions

• Novel imaging technologies:

  • Expansion microscopy with CDS2 antibodies provides enhanced spatial resolution

  • Volumetric imaging techniques combined with clearing methods enable 3D visualization of CDS2 distribution

  • Live-cell antibody fragment imaging approaches track CDS2 dynamics in real-time

These approaches leverage CDS2 antibodies to advance our understanding of fundamental cellular processes and potential therapeutic interventions.